The article focuses on the approval of the U.S. Food and Drug Administration (FDA) for the development of the drug anti-interleukin-6 (IL-6) Sylvant by the pharmaceutical company Janssen, for the treatment of Castleman's disease, a B-cell lymphoproliferative disorder.